News > Article Published:
Alzheimer's Disease Research

Light and Sound Therapy Slows Cognitive Decline in People with Mild Alzheimer’s Disease

The HOPE Study, a pivotal clinical trial testing an at-home light and sound stimulation for Alzheimer’s disease, showed promise for this type of treatment.

A woman is seated cross-legged in a chair. She is wearing a device that looks like headphones connected to a set of VR glasses.

Key Takeaways

  • Spectris is an investigational, non-invasive device from Cognito that delivers 40 Hz audiovisual stimulation at home in people with mild-to-moderate Alzheimer’s disease.
  • A large clinical trial with 673 total participants tested daily use of Spectris therapy vs. control in people with mild-to-moderate Alzheimer’s disease.
  • The trial did not meet its primary endpoint overall, but findings in people with mild Alzheimer’s showed daily use of Spectris slowed cognitive decline across clinical and functional measures.

 

A large clinical trial of a wearable light and sound device, called Spectris, showed promising results in slowing disease progression in people with mild Alzheimer’s disease. Cognito presented findings from its HOPE study at the Clinical Trials on Alzheimer’s Disease (CTAD) conference on November 16, 2026, in Boston, Massachusetts.

While the study did not meet its primary endpoint of significantly improving cognitive and functional abilities in the overall study population, in the pre-specified mild Alzheimer’s group, Spectris slowed decline versus sham on all five efficacy measures, by 28.6% to 55.8%. This positively impacted the parts of life that people living with Alzheimer’s disease and their families have said are most important.

Learn more about the HOPE Study Results

Register today to join Marwan Noel Sabbagh, MD, for an in-depth discussion of Spectris and the HOPE trial results on the December 3, 2026, episode of Zoom In on Dementia & Alzheimer’s

 

What the study tested

The HOPE trial enrolled 673 people with mild-to-moderate Alzheimer’s disease. It compared the effects of Spectris with a similar device that looked the same but did not deliver an active treatment. The goal was to see whether Spectris could slow decline over the course of 12 months, as assessed by combining measures of cognition (thinking abilities) and daily function (everyday activities).

Spectris is worn over the eyes and ears for about an hour a day and delivers light and sound pulsing 40 times per second. This type of stimulation has been shown to boost gamma waves, which are a type of brain rhythm linked to memory and attention. In Alzheimer’s, these gamma waves are disturbed, and the theory is that boosting them with Spectris could slow some of the effects of the disease. The treatment is non-invasive and can be done at home.

What researchers found

  • Mild Alzheimer’s: Participants with mild Alzheimer’s who used the device daily as directed declined 28.6% to 55.8% slower than those using sham.
  • Daily users: People who used the device and were 70% compliant with the protocol for at least 6 months, showed 64% to 82% slower decline compared to the untreated group. This held across three important measures: daily function, the ability to handle complex tasks, and cognition.
  • Safety: The device was well tolerated. The most commonly reported side effects were minor, such as headache and ringing in the ears (tinnitus).

What’s next

Spectris is investigational and has not been cleared by the FDA. While the study did not meet its main goal across all participants with mild-to-moderate Alzheimer’s, the findings in people with mild Alzheimer’s support its use in that group of people. Cognito plans submit the mild results to the FDA and work with the Agency to, hopefully, bring a new approach to treating people with mild Alzheimer’s disease.

Building on brain-rhythm science

Cognito’s results add to a growing field of research into whether restoring the brain’s natural rhythms can help protect it from Alzheimer’s. BrightFocus’s Alzheimer’s Disease Research program grantee Annabelle Singer, PhD is one of the scientists behind the early lab discoveries showing that 40 Hz light and sound reduced Alzheimer’s-related changes in mice. With BrightFocus funding, her lab is now exploring new uses for this kind of stimulation, including how it affects the brain’s immune cells and whether it can protect the brain from the harmful effects of chronic stress. Research like hers helps scientists understand how these therapies work, and who they might help most.

About BrightFocus Foundation

BrightFocus Foundation is a premier global nonprofit funder of research to defeat Alzheimer’s, macular degeneration, and glaucoma. Since its inception more than 50 years ago, BrightFocus and its flagship research programs—Alzheimer’s Disease Research, Macular Degeneration Research, and National Glaucoma Research—has awarded more than $330 million in research grants to scientists around the world, catalyzing thousands of scientific breakthroughs, life-enhancing treatments, and diagnostic tools. We also share the latest research findings, expert information, and resources to empower the millions impacted by these devastating diseases. Learn more at brightfocus.org.

Disclaimer: The information provided here is a public service of BrightFocus Foundation and is not intended to constitute medical advice. Please consult your physician for personalized medical, dietary, and/or exercise advice. Any medications or supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical products or therapies.

Share this post